<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05021991</url>
  </required_header>
  <id_info>
    <org_study_id>PRAX-944-222</org_study_id>
    <nct_id>NCT05021991</nct_id>
  </id_info>
  <brief_title>A Clinical Trial of 3 Doses of PRAX-944 in Participants With Essential Tremor</brief_title>
  <official_title>A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose Range Finding Clinical Trial to Evaluate the Tolerability, Safety, and Efficacy of PRAX-944 in the Treatment of Adults With Essential Tremor</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Praxis Precision Medicines</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Praxis Precision Medicines</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized, double-blind, placebo-controlled clinical trial to evaluate the&#xD;
      tolerability, safety, and efficacy of 20, 60, and 120 mg oral PRAX-944 compared to placebo in&#xD;
      the treatment of adults with essential tremor. Blood levels of PRAX-944 will also be measured&#xD;
      throughout the trial.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 14, 2021</start_date>
  <completion_date type="Anticipated">October 2022</completion_date>
  <primary_completion_date type="Anticipated">September 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence and severity of Adverse Events (AE)</measure>
    <time_frame>56 days</time_frame>
    <description>An AE is any untoward medical occurrence in a clinical trial participant, temporally associated with the use of study drug, whether or not considered related to the study drug.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline to Day 56 on the Essential Tremor Rating Assessment Scale (TETRAS) combined upper limb (CUL) score</measure>
    <time_frame>56 days</time_frame>
    <description>The TETRAS is an essential tremor and activities of daily living rating scale. The full scale has 2 sections, the Performance subscale (PS) and the ADL subscale. The PS consists of 9 items covering different body regions. The TETRAS PS CUL aggregates 4 items rating tremor of the upper limb body region. These 4 items are rated on a 5-point scale (ranging from 0 to 4). One item, Item 4, consists of ratings for 3 tasks rated separately for upper limbs on both sides of the body for a total of 6 ratings. The total score of the 4 items (9 ratings) ranges from 0 to 54 with higher scores indicating greater tremor severity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline to Day 56 on the TETRAS Activities of Daily Living (ADL) score</measure>
    <time_frame>56 days</time_frame>
    <description>The TETRAS is an essential tremor and ADL rating scale. The full scale has 2 sections, the Performance subscale and the ADL subscale. The ADL subscale consists of 12 items measuring the impact of essential tremor on typical daily activities. These 12 items are rated on a 5-point scale (ranging from 0 to 4). The total score of the 12 items ranges from 0 to 60 with higher scores indicating greater tremor severity.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Incidence of AEs by preferred term</measure>
    <time_frame>56 days</time_frame>
    <description>The incidence of AEs will be reported by preferred term, including any terms related to clinically significant changes in body temperature, pulse rate, respiratory rate, blood pressure (systolic and diastolic), clinical laboratory measures (chemistry, hematology, urinalysis, and coagulation), and electrocardiogram parameters (heart rate, PR, QRS, QT, and corrected QT intervals).</description>
  </other_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">112</enrollment>
  <condition>Essential Tremor</condition>
  <arm_group>
    <arm_group_label>PRAX-944 (120 mg)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Once daily, oral dosing with titration to 120 mg: 3 days of 20 mg, 4 days of 40 mg, 7 days of 60 mg, 7 days of 80 mg, 7 days of 100 mg, 28 days of 120 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PRAX-944 (60 mg)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Once daily, oral dosing with titration to 60 mg: 3 days of 20 mg, 4 days of 40 mg, 49 days of 60 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PRAX-944 (20 mg)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Once daily, oral dosing: 56 days of 20 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Once daily, oral dosing: 56 days of placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>120 mg PRAX-944</intervention_name>
    <description>Once daily oral treatment with titration</description>
    <arm_group_label>PRAX-944 (120 mg)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>60 mg PRAX-944</intervention_name>
    <description>Once daily oral treatment with titration</description>
    <arm_group_label>PRAX-944 (60 mg)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>20 mg PRAX-944</intervention_name>
    <description>Once daily oral treatment</description>
    <arm_group_label>PRAX-944 (20 mg)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Once daily oral treatment</description>
    <arm_group_label>PRAX-944 (20 mg)</arm_group_label>
    <arm_group_label>PRAX-944 (60 mg)</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Clinical diagnosis of ET, including: (a) tremor syndrome of bilateral upper limb&#xD;
             action tremor, (b) at least 3 years in duration, (c) with or without tremor in other&#xD;
             locations (eg, head, voice, or lower limbs), (d) If the symptoms and signs are judged&#xD;
             by the investigator to be due to the diagnosis of ET, it is acceptable for them to&#xD;
             also have one or more of the following ET plus signs: (i) mild dystonic posturing,&#xD;
             (ii) mild rest tremor in the setting of advanced ET and in the absence of other&#xD;
             features of Parkinsonism, (iii) intention tremor, (iv) mild increase in tandem gait&#xD;
             difficulty.&#xD;
&#xD;
          2. TETRAS upper limb score (ie, sum of bilateral upper limb items 4a, 4b, and 4c) of â‰¥10&#xD;
             as rated by the Investigator at Screening and Baseline.&#xD;
&#xD;
          3. If currently receiving any medication for ET, is on a stable dose of any of these&#xD;
             medications for ET for 1 month prior to Screening and is willing to maintain stable&#xD;
             doses throughout the trial. If receiving primidone for ET, is willing and able to&#xD;
             discontinue 14 days prior to Day 1.&#xD;
&#xD;
          4. Body mass index (BMI) between 18 and 40 kg/m2 (inclusive).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Sporadically using a benzodiazepine, sleep medication, or anxiolytic that would&#xD;
             confound the assessment of tremor.&#xD;
&#xD;
          2. Trauma to the nervous system within 3 months preceding the onset of tremor.&#xD;
&#xD;
          3. History or clinical evidence of other medical, neurological, or psychiatric condition&#xD;
             that may explain or cause tremor, including but not limited to Parkinson's disease,&#xD;
             Huntington's disease, Alzheimer's disease, cerebellar disease (including&#xD;
             spinocerebellar ataxias), primary dystonia, Fragile X Tremor/Ataxia syndrome or family&#xD;
             history of Fragile X syndrome, traumatic brain injury, psychogenic tremor, alcohol or&#xD;
             benzodiazepine abuse or withdrawal, multiple sclerosis, polyneuropathy, and endocrine&#xD;
             states such as hyperthyroidism or unstable treatment of hypothyroidism or medication,&#xD;
             food, or supplement induced movement disorders (eg, tremor related to beta agonists or&#xD;
             caffeine), or other medical, neurological, or psychiatric conditions that may explain&#xD;
             or cause tremor&#xD;
&#xD;
          4. Prior magnetic resonance-guided focused ultrasound or surgical intervention for ET&#xD;
             such as deep brain stimulation or thalamotomy.&#xD;
&#xD;
          5. Botulinum toxin injection for ET in the 6 months prior to Screening.&#xD;
&#xD;
          6. Cala trio health device for ET in 14 days prior to Baseline and throughout the study.&#xD;
&#xD;
          7. History of substance use disorder&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>VP, Clinical Development</last_name>
    <role>Study Director</role>
    <affiliation>Praxis Precision Medicines</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Chief Medical Officer, Praxis Precision Medicines</last_name>
    <phone>617-300-8460</phone>
    <email>clinicaltrials@praxismedicines.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Praxis Research Site</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35294</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Praxis Research Site</name>
      <address>
        <city>Santa Monica</city>
        <state>California</state>
        <zip>90404</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Praxis Research Site</name>
      <address>
        <city>Port Charlotte</city>
        <state>Florida</state>
        <zip>33980</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Praxis Research Site</name>
      <address>
        <city>Saint Petersburg</city>
        <state>Florida</state>
        <zip>33713</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Praxis Research Site</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Praxis Research Site</name>
      <address>
        <city>West Palm Beach</city>
        <state>Florida</state>
        <zip>33407</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Praxis Research Site</name>
      <address>
        <city>Kansas City</city>
        <state>Kansas</state>
        <zip>66160</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Praxis Research Site</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02118</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Praxis Research Site</name>
      <address>
        <city>Farmington Hills</city>
        <state>Michigan</state>
        <zip>48334</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Praxis Research Site</name>
      <address>
        <city>Golden Valley</city>
        <state>Minnesota</state>
        <zip>55427</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Praxis Research Site</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Praxis Research Site</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Praxis Research Site</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45212</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Praxis Research Site</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Praxis Research Site</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Praxis Research Site</name>
      <address>
        <city>Spokane</city>
        <state>Washington</state>
        <zip>99202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>August 20, 2021</study_first_submitted>
  <study_first_submitted_qc>August 20, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 26, 2021</study_first_posted>
  <last_update_submitted>October 28, 2021</last_update_submitted>
  <last_update_submitted_qc>October 28, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Movement Disorder</keyword>
  <keyword>Benign Essential Tremor</keyword>
  <keyword>Familial Tremor</keyword>
  <keyword>Hereditary Essential Tremor</keyword>
  <keyword>Movement Disorder Agents</keyword>
  <keyword>Calcium Channels, T-type</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tremor</mesh_term>
    <mesh_term>Essential Tremor</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pramoxine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

